Ryvu Therapeutics has reported a PLN 24.24m net loss from continuing operations
According to a company report, Ryvu Therapeutics recorded a PLN 24.24m standalone net loss from continuing operations in the second quarter of 2021. This is higher than last year when the loss amounted to PLN 4.3m. The company also suffered a higher operating loss and EBITDA loss from continuing operations than in 2020. Ryvu Therapeutics…